ABOUT THIS CONFERENCE
HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurodegenerative, immunologic, metabolic, inflammatory and cardiovascular disorders. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that can cause adverse cellular effects and unwanted toxicity. Cambridge Healthtech Institute's seventh annual conference on Next Generation Histone Deacetylase Inhibitors, tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family.
SUGGESTED EVENT PACKAGE:
September 23: Characterization and Quantification of Histone Modifications Short Course
September 24 - 25: Targeting Epigenetic Readers Conference
September 25: Tools for Detection and Utilization of Epigenetic Markers Dinner Short Course
September 25 - 26: Next Generation Histone Deacetylase Inhibitors Conference
FEATURED PRESENTATION: Targeting Lysine Acetylation in Human Disease
James E. Bradner, M.D., Assistant Professor, Department of Medicine, Harvard Medical School; Investigator, Department of Medical Oncology, Dana-Farber Cancer Institute
Sirtuins in Aging and Disease
Leonard P. Guarente, Ph.D., Novartis Professor of Biology, Harvard University
Chemogenomic Approaches to Spatiotemporal Regulation of HDAC Activity
Ralph Mazitschek, Ph.D., Assistant Professor, Center for Systems Biology, Chemical Biology Platform, Massachusetts General Hospital
Novel Lysine Acylation Pathways and Acetylation-Independent Mechanisms of HDACs
Yingming Zhao, Ph.D., Professor, The Ben May Department for Cancer Research, University of Chicago
HDAC Inhibitors for the Treatment of Pathological Muscle Remodeling
Timothy A. McKinsey, Ph.D., Associate Professor and Associate Division Head for Translational Research, Department of Medicine, Division of Cardiology, University of Colorado Denver
HDAC Inhibition to Target Heart Disease
Joseph Hill, M.D., Ph.D., Professor, Internal Medicine and Molecular Biology, Chief of Cardiology, University of Texas Southwestern Medical Center; Director, Harry S. Moss Heart Center
HDAC Inhibition and Cardiac Protection
Ting Zhao, M.D., Associate Professor, Department of Surgery, Roger Williams Medical Center, Boston University Medical School
HDACi in the Treatment of Muscular Dystrophies: Targeting Cellular and Molecular Networks that Control Muscle Repair
Puri Pier Lorenzo, M.D., Ph.D., IRCCS Fondazione Santa Lucia, Pharmacology and Epigenetics, Rome, Italy; Associate Professor, Sanford-Burnham Institute for Medical Research
Regulation of Excitatory and Inhibitory Synaptic Functions by HDAC2
Qiang Zhou, Ph.D., Scientist, Department of Neuroscience, Genentech Inc.
Immuno-Modulatory Activity of HDAC Inhibitors
Tso-Pang Yao, Ph.D., Associate Professor, Department of Pharmacology and Cancer Biology, Duke University
HDAC6 and Immune Sexual Dimorphism: New Approaches to Autoimmunity
Wayne W. Hancock, M.D., Ph.D., Professor of Pathology and Chief of Transplant Immunology, Children's Hospital of Philadelphia and University of Pennsylvania
Design of Class I Isoform Selective Inhibitors for Use in Non-Oncology Indications
Edward Holson, Ph.D., Director, Medicinal Chemistry, Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard
Inhibition of HDAC3 Protects Beta-Cell Function
Bridget K. Wagner, Ph.D., Director, Pancreatic Cell Biology, Chemical Biology Program, The Broad Institute of MIT and Harvard